## Supplementary materials

Sustained delivery of prilocaine and lidocaine using depot microemulsion system: In vitro, ex vivo and in vivo animal studies

Xiaomin Zhang ${ }^{\text {a }}$, Minyan Dang ${ }^{\text {b }}$, Wenzhi Zhang ${ }^{\text {b }}$, Yan Lei ${ }^{\text {b }}$, Wentao Zhou ${ }^{\text {c }}$
${ }^{\text {a }}$ Department of Neurology, The Second People's Hospital of Yunnan Province, Yunnan, 650021, China
${ }^{\text {b }}$ Innoscience Research Sdn Bhd, Jalan Subang Jaya, Selangor, 47650, Malaysia
c Department of Anesthesiology, High-tech Branch of Shaanxi Second People's Hospital, Shaanxi, 710005, China

* Corresponding author at: Department of Anesthesiology, High-tech Branch of Shaanxi Second People's Hospital, No. 3 Gaoxin Road, Xi'an, Shaanxi, 710005, China

Tel.: +86 18991211559
E-mail address: seygx123@sina.com (W. Zhou)

## Supplementary material Part I: Pseudo-ternary phase diagrams



Fig. SM-1. Pseudo-ternary phase diagrams at $S_{\text {mix }}[1: 2(A)$ and 1:4 (B)]. Smix $=$ Pluronic F127: PEG 200.

## Supplementary material Part II: TEM images



Supplementary material Part III: Stability of microemulsions with time
Table
Transmittance data of LD-(1:4)-3 and PR-(1:4)-3 batches.

| Batches | Day-1 | Day-30 | Day-60 | Day-90 |
| :---: | :---: | :---: | :---: | :---: |
| LD-(1:4)-3 | $98.2 \pm 0.2$ | $99.1 \pm 0.1$ | $98.8 \pm 0.2$ | $99.1 \pm 0.2$ |
| PR-(1:4)-3 | $99.5 \pm 0.1$ | $98.8 \pm 0.2$ | $99.6 \pm 0.1$ | $99.4 \pm 0.2$ |

## Supplementary material Part IV: Thermodynamic stability

## Table

Thermodynamic stability data of lidocaine and prilocaine loaded microemulsions.

| Batches | Visual appearance | Centrifugation | Heatingcooling cycles | Freeze thaw cycles |
| :---: | :---: | :---: | :---: | :---: |
| LD-(1:2)-1 | Transparent | $\checkmark$ | $\checkmark$ | $\times$ |
| LD-(1:2)-2 | Transparent | $\checkmark$ | $\checkmark$ | $\times$ |
| LD-(1:4)-3 | Transparent | $\checkmark$ | $\checkmark$ | $\checkmark$ |
| LD-(1:4)-4 | Transparent | $\checkmark$ | $\checkmark$ | $\checkmark$ |
| PR-(1:2)-1 | Transparent | $\sqrt{ }$ | $\checkmark$ | $\times$ |
| PR-(1:2)-2 | Transparent | $\checkmark$ | $\checkmark$ | $\times$ |
| PR-(1:4)-3 | Transparent | $\checkmark$ | $\checkmark$ | $\checkmark$ |
| PR-(1:4)-4 | Transparent | $\checkmark$ | $\checkmark$ | $\checkmark$ |

Supplementary material Part V: Skin irritation study images

Marketed ointment USP



PR-(1:4)-4


